ASSOCIATION OF A CB1 RECEPTOR ANTAGONIST AND A PRODUCT THAT ACTIVATES DOPAMINERGIC NEUROTRANSMISSION INTO THE BRAIN, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE THEREOF FOR THE TREATMENT OF THE DISEASE

摘要

The invention relates to the association of one or more CB1 antagonist azetidine derivatives and one or more products that activate dopaminergic neurotransmission in the brain, the pharmaceutical compositions containing same and the use thereof for the treatment of Parkinson's disease.